Last update 17 Jul 2025

US20220296593

Patent Mining

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms-
Target
LDLR x PCSK9
Action
modulators
Mechanism
LDLR modulators(LDL receptor modulators), PCSK9 modulators(Proprotein convertase subtilisin kexin type 9 modulators)
Therapeutic Areas
Cardiovascular DiseasesEndocrinology and Metabolic DiseaseEye Diseases+ [2]
Active Indication
Cardiovascular DiseasesChronic Kidney DiseasesEndocrinology and Metabolic Disease+ [2]
Inactive Indication-
Originator Organization
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.Institut de Cardiologie De Montreal
Active Organization
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.Institut de Cardiologie De Montreal
Inactive Organization-
License Organization-
Drug Highest PhaseDiscovery
First Approval Date-
Regulation-

Related

100 Clinical Results associated with US20220296593
Login to view more data
100 Translational Medicine associated with US20220296593
Login to view more data
100 Patents (Medical) associated with US20220296593
Login to view more data
100 Deals associated with US20220296593
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesDiscovery-
Institut de Cardiologie De Montreal
22 Sep 2022
Cardiovascular DiseasesDiscovery-
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.
22 Sep 2022
Chronic Kidney DiseasesDiscovery-
Institut de Cardiologie De Montreal
22 Sep 2022
Chronic Kidney DiseasesDiscovery-
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.
22 Sep 2022
Endocrinology and Metabolic DiseaseDiscovery-
Institut de Cardiologie De Montreal
22 Sep 2022
Endocrinology and Metabolic DiseaseDiscovery-
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.
22 Sep 2022
InflammationDiscovery-
Institut de Cardiologie De Montreal
22 Sep 2022
InflammationDiscovery-
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.
22 Sep 2022
Retinal DiseasesDiscovery-
Institut de Cardiologie De Montreal
22 Sep 2022
Retinal DiseasesDiscovery-
Affina Biotechnologies, Inc.Affina Biotechnologies, Inc.
22 Sep 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free